against *C. trachomatis* caused sexually transmitted diseases. The variable domains also represent the primary serotyping antigenic determinants of *C. trachomatis* organisms making these variable domain sequences potential useful targets for the development of DNA or antibody based diagnostic assays for *C. trachomatis*. The invention is described further in Ying et al., Infection & Immunity *57*, 1040–1049, 1989. Zhang et al., J. Infect. Dis. *176*, 1035–1040, 1997 describes DNA vaccines utilizing MOMP DNA.

Dated: May 21, 1998.

Jack Spiegel,

Director, Division of Technology, Development and Transfer, Office of Technology Transfer.

[FR Doc. 98–14496 Filed 6–1–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Pubic Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Applicator System And Method Of Use

MJ Lenardo, G Fisher (NIAID)

Serial No. 09/005,475 Filed 12 Jan 98

Licensing Contact: John Fahner-Vihtelic, 301/496–7735 ext. 270.

The present application describes a novel microcentrifuge tube and tube cap and research method, which allows for dispensing the contents of a microcentrifuge tube without pipetting. The design eliminates pipetting volume error and prevents the cross-contamination which can be experienced in conventional pipetting. This invention is particularly useful for such applications as loading tube contents into an electrophoresis gel after a reaction such as PCR. Using the disclosed apparatus and methods increases the speed of a variety of routine procedures and prevents contamination of samples due to soiled lab apparatus.

Linking Compounds Useful For Coupling Carbohydrates To Amine-Containing Carriers

P Kova, J Zhang (NIDDK)

Serial No. 60/069,686 Field 12 Dec 97

Licensing Contact: Robert Benson, 301/496–7056 ext. 267.

This invention describes an inexpensive and easy method of linking carbohydrates and carriers containing an amino group to form neoglycoconjugates. The resulting neoglycoconjugates are useful as vaccines (i.e., bacterial LPS or LOS-carrier protein conjugate vaccines) or as biologically active chromatographic substrates (i.e., carbohydrates bound to aminopropyl glass). The method involves specific linkers that are easily made from inexpensive commercially available starting materials. The carbohydrates to be used in the method are limited only by the ability to convert such carbohydrates into glycosyl donors. Claimed are the linkers, conjugates made with the linkers and intermediates, and methods of synthesizing the linkers and conjugates. The invention is described in Tetrahedron letters 39, 1091–1094, 1998.

System And Method For Intelligent Quality Control Of A Process

JM DeLeo (CIT), AT Remaley (CC)

Serial No. 60/066,624 Filed 26 Nov 97

Licensing Contact: John Fahner-Vihtelic, 301/496–7735 ext. 270.

The present application is a methodology for monitoring the quality control of a process on-line for the purpose of predicting and preventing unusual/untoward events or failures in that process. Such processes include (but are not limited to) acquisition of medical data from laboratory instruments, assembly line manufacturing, and general plant or factory operations. The methodology is based on a two-tiered automated intelligent agent architecture. Intelligent agents in the first tier are neural networks trained to detect specific errors for specific process environment parameters. The single-agent second tier is an expert system that integrates inputs from first tier agents to derive corrective action decisions that are manually or automatically executed in the process environment. Error prevalence and wrong-decision cost information are factored into the action decision-making process. For clinical laboratory instruments, the method monitors patient laboratory data and provides significant improvement in quality control at reduced cost compared to existing methods.

Identification Of The Human Pendred Syndrome Gene

E Green, et al. (NHGRI)

DHHS Reference No. E–004–98/0 Filed 28 Oct 97

Licensing Contact: Dennis Penn, 301/496–7065, ext. 211.

Pendred syndrome is a recessively inherited disorder which was poorly understood until the discovery of the Pendred syndrome gene. This syndrome, which is associated with congenital deafness and thyroid goiter, may account for upwards of 10% of hereditary deafness. The gene encodes for the protein pendrin which transports sulfate across cell membranes. However, the gene, when mutated, is responsible for producing defective pendrin and causing Pendred syndrome. Pendrin therefore plays a key role in thyroid function and the development and functioning of the auditory system. Learning how pendrin functions could lead to a better understanding of thyroid function and the development of the auditory system. Finally, the resulting knowledge into the genetic basis of Pendred syndrome will allow for improved diagnosis of syndrome-specific mutations in at-risk individuals. This research has been published in Nature Genetics 1997 December; 17(4):411–22.

Local Magnetization Spoiling Using A Gradient Insert For Reducing The Field Of View In Magnetic Resonance Imaging

DG Wiesler, H Wen, RS Balaban, SD Wolff (NHLBI)

Serial No. 60/043,292 Filed 11 Apr 97

Licensing Contact: John Fahner-Vihtelic, 301/496–7735, ext. 270.

The present invention provides a method and device for eliminating alias artifacts encountered in MRI when the field of view is made smaller than the subject being imaged. Significant

advantages accrue from reducing the field of view to a smaller region of interest. These include reduced imaging time, increased spatial and temporal resolution, and less susceptibility to motion artifacts. The device operates by dephasing the magnetic resonance signal in regions away from the region of interest by means of a gradient insert.

Nitrogen-Containing Cylohetero Cycloalkyl-Aminoaryl Derivatives For CNS Disorders

BR DeCosta, et al. (NIDDK)

Serial No. 07/473,008 Filed 31 Jan 90 (U.S. Patent 5,130,330 Issued on 14 Jul 92); Serial No. 07/877,190 Filed 01 Jul 92 (U.S. Patent 5,739,158 Issued on 14 Apr 98); Serial No. 08/335,532 Filed 07 Nov 94

Licensing Contact: Charles Maynard, 301/496–7735, ext. 243.

This technology includes compositions for a novel family of nitrogen containing cyclohetero cycloalkyl-aminoaryl compounds for use in the field of clinical neurology. The intellectual property relates specifically to a class of therapeutically useful compounds for the treatment of central nervous system (CNS) disorders such as cerebral ischemia, psychotic disorders and convulsions. These compounds are particularly useful for treating neurotoxic injury which follow periods of hypoxia, anoxia or ischemia associated with stroke, cardiac arrest or perinatal asphyxia.

The novel semirigid derivatives (+)-cis-1-[2-phenyl-2-bicyclo[3,1,0]hexyl]piperidine [(+)-8], its enantiomer (−)-8, and (+−)-trans-1-[2-phenyl-2-bicylo [3,1,0]piperidine [(+/−)-9] are illustrative examples of this family of compounds which may be used to treat CNS disorders and diseases such as cerebral ischemia, psychotic disorders and convulsions, as well as prevention of neurotoxic damage and neurodegenerative disease via a unique receptor mechanism. This class of compounds produce neuroprotective effects by a different mechanism to phencyclidine and metaphit a non-competitive N-methyl-D-aspartic acid antagonis.

Dated: May 21, 1998.

Jack Spiegel,

Director, Division of Technology, Development, and Transfer, Office of Technology Transfer.

[FR Doc. 98–14497 Filed 6–1–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Cancer Screening Trial Expansion.

Date: June 8–9, 1998.

Time: June 8—8:00 a.m. to recess; June 9—8:00 a.m. to Adjournment.

Place: Double Tree Hotel-Rockville, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Wilna Woods, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 622B, 6130 Executive Boulevard, MSC 7405, Bethesda, MD 20892–7405, Telephone: 301/496–7903.

Purpose/Agenda: To review, discuss and evaluate responses to a Request for Proposal.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower, 93.399, Cancer Control.)

Dated: May 22, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98–14494 Filed 6–1–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Institute of Mental Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: June 24, 1998.

Time: 8:30 a.m.

Place: Chevy Chase Holiday Inn, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: W. Gregory Zimmerman, Parklawn, Room 9C–18, 5600 Fishers Lane, Rockville, Md 20857, Telephone: 301, 443–1340.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers 93.242, 93.281, 93.282)

Dated: May 22, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98–14493 Filed 6–1–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; National and Regional Meetings of the National Reading Panel

Notice is hereby given of five regional meetings and one national meeting of the National Reading Panel. The regional meetings will be held on May 29, 1998, in Chicago, Illinois; June 5, 1998, in Portland Oregon, June 8, 1998, in Houston, Texas; June 23, 1998 in New York City, New York; and July 9, 1998, in Jackson, Mississippi. The national meeting will be held July 24, 1998, in Bethesda, Maryland. The regional meeting in Chicago will take place at Illinois Room at the Chicago Circle Center (CCC), University of Illinois at Chicago, 750 South Halsted Street, Chicago, IL 60607. The Chicago meeting will begin at 9:30 a.m. and is expected to adjourn at 4:00 p.m. The entire meeting will be open to the public. The precise times and sites for the other meetings listed will be published when the plans for the meetings at those sites are finalized.

The National Reading Panel was requested by Congress and created by the Director of the National Institute of Child Health and Human Development in consultation with the Secretary of Education. The Panel will study the